

In Vivo Star Anti-Mouse CD274 (PD-L1) Antibody

Catalog Number:	507701, 507702, 507703
Size:	1 mg, 5 mg, 25 mg
Target Name:	mouse PD-L1, CD274
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	10F.9G2.1-m2a5L
Application:	ELISA, WB, Flow cytometry, IHC, ICC, animal model study
Reactivity:	Mouse
Format:	Liquid
Product Description:	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody
Isotype:	Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa
Antibody Type:	Recombinant
Purity:	>95% by reducing SDS-PAGE
Endotoxin:	< 1 EU per 1 mg of the protein by the LAL method.
Storage Conditions:	4°C
Grade:	In vivo
Recommended Usage:	This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
Hidden Synonyms:	InVivoMab, InVivoPlus, GoInVivo, In Vivo Gold

BACKGROUND INFORMATION

PD-L1 (Programmed Death-Ligand 1), also known as CD274 or B7-H1, is a 40 kDa type I transmembrane protein belonging to the B7 family within the immunoglobulin receptor superfamily. The protein contains immunoglobulin V-like and C-like domains and is expressed by a wide range of hematopoietic and non-hematopoietic cells, including T cells, B cells, NK cells, dendritic cells, monocytes, endothelial cells, and various tumor cells. PD-L1 serves as a ligand for PD-1 (CD279) and plays a critical role in immune regulation by inhibiting T-cell activation, proliferation, and cytokine production upon engagement with PD-1. This interaction maintains immune homeostasis during infection or inflammation, preventing autoimmunity. However, in tumor microenvironments, PD-L1 expression enables immune evasion by suppressing cytotoxic T-cell function, contributing to tumor progression. PD-L1 expression is considered prognostic in several malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. The PD-1/PD-L1 axis is a major target in cancer immunotherapy.